PA
ENTA icon

Pinnacle Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Pinnacle Associates’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-74,750
Closed -$2.7M – 656
2015
Q3 		$2.7M Buy
74,750
+1,650
+2% +$70.9K 0.06% 254
2015
Q2 		$3.29M Buy
+73,100
New +$2.84M 0.06% 242

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Pinnacle Associates's ENTA Position: Q4 2015 in Review

Pinnacle Associates sold out of Enanta Pharmaceuticals (ENTA) in Q4 2015, closing a stake of 74,750 shares — an estimated $2.7M sold.

Pinnacle Associates first reported a position in ENTA in Q2 2015 and held it in 2 quarters. The position peaked at $3.29M in Q2 2015. 136 funds tracked by Wall St. Rank hold ENTA as of Q4 2015.

  • Pinnacle Associates reported no remaining Enanta Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Pinnacle Associates sold 74,750 Enanta Pharmaceuticals shares in Q4 2015, an estimated $2.7M.
  • Pinnacle Associates first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Pinnacle Associates's Enanta Pharmaceuticals position peaked at $3.29M in Q2 2015.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2015.

Based on Pinnacle Associates's 13F filing for Q4 2015, filed 9 Feb 2016.